Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial

Abstract

AbstractPatients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short‐term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice‐daily aspirin dosing restores persistent platelet thromboxane (TX) inhibition. However, the long‐term pharmacodynamic efficacy, safety and tolerability of twice‐daily aspirin remain untested. We performed a multicenter, randomized, open‐label, blinded‐endpoint, phase‐2 trial in which 242 patients with ET were randomized to 100 mg aspirin twice‐ or once‐daily and followed for 20 months. The primary endpoint was the persistence of low serum TXB2, a surrogate biomarker of antithrombotic efficacy. Secondary endpoints were major and clinically relevant non‐major bleedings, serious vascular events, symptom burden assessed by validated questionnaires, and in vivo platelet activation. Serum TXB2 was consistently lower in the twice‐daily versus once‐daily regimen on 10 study visits over 20 months: median 3.9 ng/mL versus 19.2 ng/mL, respectively; p < .001; 80% median reduction; 95% CI, 74%–85%. No major bleeding occurred. Clinically relevant non‐major bleedings were non‐significantly higher (6.6% vs. 1.7%), and major thromboses lower (0.8% vs. 2.5%) in the twice‐daily versus once‐daily group. Patients on the twice‐daily regimen had significantly lower frequencies of disease‐specific symptoms and severe hand and foot microvascular pain. Upper gastrointestinal pain was comparable in the two arms. In vivo platelet activation was significantly reduced by the twice‐daily regimen. In patients with ET, twice‐daily was persistently superior to once‐daily low‐dose aspirin in suppressing thromboxane biosynthesis and reducing symptom burden, with no detectable excess of bleeding and gastrointestinal discomfort.